Investors Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually large options trading activity on Wednesday. Stock investors bought 1,002 put options on the company. This is an increase of 1,791% compared to the average volume of 53 put options.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MRVI shares. Wolfe Research began coverage on shares of Maravai LifeSciences in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Robert W. Baird lowered their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Royal Bank of Canada cut their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. Finally, Guggenheim initiated coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.28.

Insiders Place Their Bets

In other Maravai LifeSciences news, insider Carl Hull acquired 175,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $5.64 per share, with a total value of $987,000.00. Following the transaction, the insider now owns 175,000 shares of the company’s stock, valued at $987,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.63% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. purchased a new stake in Maravai LifeSciences in the 3rd quarter valued at approximately $600,000. Barclays PLC raised its holdings in shares of Maravai LifeSciences by 349.2% in the third quarter. Barclays PLC now owns 184,189 shares of the company’s stock worth $1,531,000 after acquiring an additional 143,184 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Maravai LifeSciences in the third quarter valued at $136,000. Geode Capital Management LLC boosted its stake in shares of Maravai LifeSciences by 6.3% during the third quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock valued at $22,874,000 after acquiring an additional 162,601 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Maravai LifeSciences during the 3rd quarter worth about $105,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Shares of MRVI stock opened at $5.33 on Thursday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock has a 50 day simple moving average of $6.12 and a 200-day simple moving average of $7.55. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -3.25 and a beta of -0.07. Maravai LifeSciences has a 12-month low of $4.28 and a 12-month high of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.